X4 Pharmaceuticals Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	2016 - 2019
Period Ending	Mar '25 Mar 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	2016 - 2019
Revenue	31.36	2.56	-	-	-	3	Upgrade
Cost of Revenue	5.51	0.8	-	-	-	-	Upgrade
Gross Profit	25.85	1.76	-	-	-	3	Upgrade
Selling, General & Admin	59.1	61.52	35.51	27.02	24.7	20.94	Upgrade
Research & Development	80.3	81.64	72.02	61.06	50.65	41.93	Upgrade
Operating Expenses	139.41	143.16	107.52	88.08	75.35	62.87	Upgrade
Operating Income	-113.56	-141.4	-107.52	-88.08	-75.35	-59.87	Upgrade
Interest Expense	-9.1	-8.77	-5.78	-3.99	-3.64	-2.69	Upgrade
Interest & Investment Income	5.73	5.77	4.58	0.22	0.01	0.27	Upgrade
Currency Exchange Gain (Loss)	-0.33	-0.33	0	-	-	-4.37	Upgrade
Other Non Operating Income (Expenses)	27.17	2.59	7.63	-2.5	0.06	4.84	Upgrade
EBT Excluding Unusual Items	-90.08	-142.14	-101.09	-94.35	-78.92	-61.82	Upgrade
Impairment of Goodwill	-	-	-	-	-9.76	-	Upgrade
Gain (Loss) on Sale of Assets	105	105	-	0.51	-	-	Upgrade
Other Unusual Items	-	-	-	-	-	-0.16	Upgrade
Pretax Income	14.92	-37.14	-101.09	-93.84	-88.68	-61.98	Upgrade
Income Tax Expense	0.33	0.31	0.08	0.03	0.02	0.15	Upgrade
Net Income	14.6	-37.45	-101.17	-93.87	-88.7	-62.13	Upgrade
Preferred Dividends & Other Adjustments	-	-	-	2.55	13.94	-	Upgrade
Net Income to Common	14.6	-37.45	-101.17	-96.41	-102.64	-62.13	Upgrade
Shares Outstanding (Basic)	7	7	6	2	1	1	Upgrade
Shares Outstanding (Diluted)	7	7	6	2	1	1	Upgrade
Shares Change (YoY)	5.89%	13.08%	179.91%	146.71%	28.25%	74.13%	Upgrade
EPS (Basic)	2.16	-5.59	-17.07	-45.53	-119.59	-92.84	Upgrade
EPS (Diluted)	2.16	-5.59	-17.07	-45.53	-119.59	-92.84	Upgrade
Free Cash Flow	-109.94	-131.23	-96.57	-77.21	-71.52	-60.18	Upgrade
Free Cash Flow Per Share	-16.28	-19.58	-16.29	-36.46	-83.33	-89.92	Upgrade
Gross Margin	82.42%	68.83%	-	-	-	100.00%	Upgrade
Operating Margin	-362.06%	-5529.96%	-	-	-	-1995.80%	Upgrade
Profit Margin	46.54%	-1464.61%	-	-	-	-2071.03%	Upgrade
Free Cash Flow Margin	-350.53%	-5132.07%	-	-	-	-2006.00%	Upgrade
EBITDA	-112.35	-140.61	-107.1	-87.57	-74.85	-59.52	Upgrade
D&A For EBITDA	1.21	0.8	0.42	0.51	0.5	0.35	Upgrade
EBIT	-113.56	-141.4	-107.52	-88.08	-75.35	-59.87	Upgrade

Updated May 1, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q